BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
4. Some definitions of exclusion criteria need explanations on how they are assessed. How and when is hemoglobin assessed? Is this different from the baseline hemoglobin assessment mentioned later? What conditions require B12 treatment in this setting per standard of care?
5. Randomization list code in Stata…I assume you will also use block 8? 6. How is allocation concealment performed? Where are bottles labeled etc?
7. "All pregnant women will also be given iron, folic acid and calcium supplements according to national guide lines." What are doses and when are they delivered? A citation would also be helpful.
8. There is a lot more information needed on the investigational product. Who makes the B12? How long is shelf-life? How many pills are in a bottle? How many bottles do women receive?
9. SAEs and safety. There are no clear safety endpoints listed. Are minor side effects like headache, itching, etc collected? What about other known B12 side effects?
10. Sample size-more information needed in the text. Figure 2 has good information on statistics but the text is much more unclear. What equations were used? 11. Outcomes: Need citation for the z-score growth reference. I assume WHO.
12. Statistical Analysis: This section needs a lot more explicit detail on the exact tests that will be used. How will differences between subgroups be assessed, what test will determine effect modification? What will be done if there is baseline imbalance for factors? I caution the authors on this section, the statistical analysis in the main paper must identically match the statistical analysis plan in the protocol or it will be considered ad hoc.
The manuscript describes a protocol for an individually randomized placebo-controlled trial of 50 mcg/d vitamin B12 supplementation from early pregnancy through six months postpartum in Nepal. The primary outcomes are Bayley-III scores at six and 12 months of age and LAZ, WAZ, and WLZ at 12 months of age. The study is welldesigned and clearly presented and has the potential to contribute to the establishment of a causal role of moderate B12 deficiency in impairment in growth and development, as well as provide evidence inform maternal health policy. A few points require clarification. COMMENTS: 1) Page 5 line 16 "common" is vague, please provide prevalence or range. 2) Page 9 line 4-7. I would also suggest measuring maternal cognition. As stated in the introduction, B12 deficiency has been associated with cognition in children and the elderly and may also affect maternal cognition during pregnancy and postpartum. 3) Page 9, line 9-12. Maternal and infant Hb and infant growth could also be mediators for developmental outcomes. 4) Page 10, line 42-46. How will the study supplements and the IFA/Ca supplements be distributed? By whom? At home or clinic? Weekly or monthly? 5) Page 12, line 13. Does weekly monitoring of compliance include both the study supplements and the standard IFA/Ca supplements? 6) Page 15, line 48-52. The ASQ-3 is a screening tool designed to detect children at risk for delay, therefore typically developing children score at ceiling (no variance in scores) which will not allow assessment of developmental trajectories. 7) Page 16, line 44-53. The eye-tracking measure is not mentioned in the study objectives and it is not clear at what time point this will be collected. 8) Page 17, line 4-10. Likewise TIMP is not mentioned in the study objectives. 9) Page 18, line 38. What will be done if there is poor agreement between field worker and supervisor? 10) Methods: Many studies have shown the importance of adaptation of tools when transferring from one context to another. Many of the tools in the current study would require adaptation, including the Bayley-III, ASQ, BISQ, ADBB, TIMP, HOME, CKCDI, and possibly the stimuli in the eye-tracking task. I don"t see a plan for adaptation and piloting of these tools or evaluation of the psychometric properties of the adapted tools, such as internal reliability and test-retest reliability. Many of these also require evaluation of inter-rater agreement for quality control. Refs: Greenfield, P. M. (1997 This manuscript reports the protocol for a vitamin B12 trial among pregnant women in Nepal. The trial will yield important results whether an available and relatively lost cost supplement may improve child growth and development. The manuscript has excellent information on the neurodevelopment tools, quality control, and data management but in my opinion could be much clearer for most other trial aspects, in particular the randomization procedures, description of investigational product, and statistical analysis. I would suggest the authors make sure all of these are clear so the trial is not inadvertently downgraded in a Cochrane review or meta-analysis. In addition, the order of the methods is hard to follow. I would suggest following the order of the SPIRIT checklist. The manuscript would also be improved with another check on grammar and punctuation. Major 1. Abstract -It would be helpful to explicitly state the primary outcomes in the abstract. Response: We have added the primary outcomes in the methods and analysis paragraph of the abstract in the revised manuscript.
2. Methods -The primary outcome is not clear since the Bayley has multiple subscales. Is the primary endpoint the composite score? Response: The primary outcomes of the trial are scores on the cognitive, language (receptive and expressive separately and composite score) and motor (fine and gross separately and composite score) subscales of the Bayley Scales of Infant and Toddler Development 3rd ed. (Bayley-III) measured at 6 and 12 months of age, and growth (length and weight) measured at 12 months of age. We have revised this throughout the manuscript.
3. Methods-The order of the paragraphs does not flow. Please consider changing to the SPIRIT order. Response: We have changed method section as per SPIRIT guidelines.
Response: We agree, and have clarified the exclusion criteria. Unfortunately, in Nepal there are no specific guidelines for B12 treatment, but it is common to prescribe vitamin B12 for treating pernicious anaemia or in strictly vegans.
5. Randomization list code in Stata…I assume you will also use block 8? Response: Yes, and we hope that this is clearer in the updated manuscript (page 11).
6. How is allocation concealment performed? Where are bottles labeled etc? Response: We will ensure allocation concealment throughout the study as none of the investigators will have access to the list that links the group identity with the id-number until completion of data collection, analysis and interpretation. Nepalese and Norwegian scientists otherwise not involved in a trial has labelled supplements.
7. "All pregnant women will also be given iron, folic acid and calcium supplements according to national guidelines." What are doses and when are they delivered? A citation would also be helpful. Response: The revised manuscript includes doses and timing of antenatal supplements under the subheading Co-intervention on page 10 with the relevant reference.
8. There is a lot more information needed on the investigational product. Who makes the B12? How long is shelf-life? How many pills are in a bottle? How many bottles do women receive? Response: We have updated the manuscript under the subheading Intervention on page 9 to include details on the investigational product. The vitamin B12 supplements are produced by GC Rieber Compact Norway with shelf life of 5 years, and it is a soft solid wafer like form. Each bar of supplement is sufficient for 8 days and participants are requested to consume one piece each day.
9. SAEs and safety. There are no clear safety endpoints listed. Are minor side effects like headache, itching, etc. collected? What about other known B12 side effects? Response: There are no known adverse effects of giving vitamin B12 orally, the maximum capacity for absorption is 2-4 µg per day and there is no reason to believe that there will be an overload (as discussed on page 11). During our weekly visits, we will ask for general adverse events such as GI symptoms and symptoms related to possible allergic reactions. This is described under "Follow-up" on page 13. 10. Sample size-more information needed in the text. Figure 2 has good information on statistics but the text is much more unclear. What equations were used? Response: We have rewritten and expanded this section on page 21, and added appropriate references for the equation used for calculating the sample size.
